Stockscreener 앱 받기
0.2205
4.38%
-0.0101
시간 외 거래:
.22
-0.0005
-0.23%
Pds Biotechnology Corp 주식(PDSB)의 최신 뉴스
PDS Biotechnology shareholders approve charter amendment and director elections - Investing.com
Form 8K PDS Biotechnology Corp For: 14 August By Investing.com - Investing.com Nigeria
PDS Biotechnology (PDSB) wins approval to double authorized stock and elect directors - Stock Titan
PDS Biotechnology (PDSB) cuts R&D spend but warns on going concern, cash at $5.6M - Stock Titan
PDSB Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
PDS Biotechnology Q2 Results: EPS misses estimate, losses widen YoY - scanx.trade
Form 8K PDS Biotechnology Corp For: 13 August By Investing.com - Investing.com South Africa
PDS Biotechnology reports Q2 2026 net loss $9.8M, cash $5.6M, strategic refocus on PDS0301 - TradingView
PDS Biotech Reports $9.8 Million Second-Quarter 2026 Net Loss - Quiver Quantitative
PDS Biotech Reports Second Quarter 2026 Financial Results - The Manila Times
PDS Biotechnology: Q2 Earnings Snapshot - Barchart.com
PDS Biotechnology Corp (NASDAQ: PDSB) Share Price, PDSB Stock News, PDSB Share Price & Updates - Kalkine
PDS Biotech Prioritizes PDS0301 After 71% Response Rate In Colorectal Cancer And Discontinues PDS0101 Phase 3 Trial - Pulse 2.0
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.34% - Investing.com
PDS Biotechnology shifts focus to PDS0301, halts PDS0101 trial By Investing.com - Investing.com South Africa
PDS Biotechnology Stock Crashes, Strategic Refocus Pivots to Metastatic Colorectal Cancer Program - Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Form 8K PDS Biotechnology Corp For: 11 August By Investing.com - Investing.com Nigeria
PDS Biotech Announces Strategic Refocus Prioritizing PDS0301 in Metastatic Colorectal Cancer (mCRC) and Partnership Strategy for PDS0101 - manilatimes.net
PDS Biotechnology prioritizes PDS0301 after Phase 2 mCRC data, halts internal PDS0101 Phase 3 spend - TradingView
PDS Biotechnology shifts focus to PDS0301, halts PDS0101 trial - Investing.com
PDS Biotechnology Refocuses on PDS0301, Ends Internal Development of PDS0101 Phase 3 Trial - Quiver Quantitative
PDS0301 Data Show 80% 24-Month Survival With Liver Metastases - Stock Titan
PDS Biotechnology Corp (PDSB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
PDS Biotechnology Corp expected to post a loss of 13 cents a shareEarnings Preview - TradingView
PDS Biotechnology Corp (PDSB) Stock News Today - TradingKey
PDS Biotechnology Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
PDSB|PDS Biotechnology Corp|Price:0.686|Chg%:-0.013 - TradingKey
PDS Biotechnology Corp (PDSB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
PDS Biotechnology Corp (PDSB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
PDS Biotechnology Corp (PDSB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
PDSB|PDS Biotechnology Corp|Price:0.699|Chg%:+0.017 - TradingKey
PDS Biotechnology Corp (PDSB) Balance Sheet - TradingKey
PDS Biotechnology Corp (PDSB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
PDS Biotechnology Corp (PDSB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
PDSB Q1 2026 Earnings: Narrower-than-Expected Loss and Clinical Progress Drive FocusCapex Guidance - dars.gov.et
PDSB|PDS Biotechnology Corp|Price:0.775|Chg%:+0.028 - TradingKey
TradingKey - TradingKey
PDSB|PDS Biotechnology Corp|Price:0.720|Chg%:+0.039 - TradingKey
PDS Biotechnology Corp. Revenue Breakdown – FWB:EU6 - TradingView
PDS Biotechnology Corp SEC Filing (Jul 22, 2026) - Stock Titan
Correction: Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight - GlobeNewswire Inc.
PDS Biotechnology (PDSB) Shows Resilience with 5.95% Gain, Testing Key Resistance at $0.80Earnings Miss Risk - dars.gov.et
PDS Biotechnology (PDSB) Nears Critical Support as Shares Decline to $0.77Small Cap Breakouts - dars.gov.et
Form S-3 PDS Biotechnology Corp For: 10 July By Investing.com - Investing.com South Africa
PDS Biotechnology (NASDAQ: PDSB) registers 13.3M shares tied to note and warrant deal - Stock Titan
PDS Biotechnology (PDSB) Slides 4.6% as Selling Pressure Weighs on Biotech StockETF Inflow Streak - dars.gov.et
PDSB | PDS Biotechnology Corporation Common Executive Compensation - Quiver Quantitative
PDS Biotechnology (PDSB) Hovers Near Support Amid Modest DeclineVolume Breadth - dars.gov.et
PDS Biotechnology (NASDAQ: PDSB) details 2026 proxy votes and pay - Stock Titan
PDS Biotechnology Corp. Actuals & Estimates (NASDAQ:PDSB) - TradingView
PDS Biotechnology Corp. Actuals & Estimates (DUS:EU6) - TradingView
PDSB Forecast — Price Target — Prediction for 2027 - TradingView
PDS Biotech’s Double Squeeze: Nasdaq Clock Ticking as Equity Dilution Looms - AD HOC NEWS
PDS Biotechnology Corp (PDSB) Institutional Confidence - TradingKey
PDS Biotechnology Corp (PDSB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
1.80%
1.77%
자본화:
|
볼륨(24시간):